[1]
|
Beaumont, J.L., Carlson, L.A., Cooper, G.R., Fejfar, Z., Fredrickson, D.S. and Strasser, T. (1970) Classification of Hy-perlipidaemias and Hyperlipoproteinaemias. Bulletin of the World Health Organization, 43, 891-915.
|
[2]
|
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年) [J]. 中华心血管病杂志, 2023, 51(3): 221-255. https://doi.org/10.3760/cma.j.cn112148-20230119-00038
|
[3]
|
Beheshti, S.O., Madsen, C.M., Varbo, A. and Nordestgaard, B.G. (2020) Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Sub-jects. Journal of the American College of Cardiology, 75, 2553-2566. https://doi.org/10.1016/j.jacc.2020.03.057
|
[4]
|
Enito-Vicente, A., Uribe, K.B., Jebari, S., Galicia-Garcia, U., Osto-laza, H. and Martin, C. (2018) Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. International Journal of Molecular Sciences, 19, Article No. 3426. https://doi.org/10.3390/ijms19113426
|
[5]
|
Singh, S. and Bittner, V. (2015) Familial Hypercholesterole-mia—Epidemiology, Diagnosis, and Screening. Current Atherosclerosis Reports, 17, Article No. 482. https://doi.org/10.1007/s11883-014-0482-5
|
[6]
|
Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S., et al. (2013) Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the Euro-pean Atherosclerosis Society. European Heart Journal, 34, 3478-3490. https://doi.org/10.1093/eurheartj/eht273
|
[7]
|
Hegele, R.A., BorÉN, J., Ginsberg, H.N., Arca, M., Averna, M., Binder, C.J., et al. (2020) Rare Dyslipidaemias, from Phenotype to Genotype to Management: A European Atherosclero-sis Society Task Force Consensus Statement. The Lancet Diabetes & Endocrinology, 8, 50-67. https://doi.org/10.1016/S2213-8587(19)30264-5
|
[8]
|
Kayikcioglu, M., Kısmalı, E., Can, L. and Payzin, S. (2014) Long-Term Follow-Up in Patients with Homozygous Familial Hypercholesterolemia, 13-Year Experience of a University Hospital Lipid Clinic. Türk Kardiyoloji Derneği Arşivi, 42, 599-611. https://doi.org/10.5543/tkda.2014.09633
|
[9]
|
Defesche, J.C., Gidding, S.S., Harada-Shiba, M., Hegele, R.A., Santos, R.D. and Wierzbicki, A.S. (2017) Familial Hypercholesterolaemia. Nature Reviews Disease Primers, 7, Article No. 17093. https://doi.org/10.1038/nrdp.2017.93
|
[10]
|
Brænne, I., Kleinecke, M., Reiz, B., Graf, E., Strom, T., Wieland, T., et al. (2016) Systematic Analysis of Variants Related to Familial Hypercholesterolemia in Families with Premature Myocardial Infarction. European Journal of Human Genetics, 24, 191-197. https://doi.org/10.1038/ejhg.2015.100
|
[11]
|
Kayikcioglu, M., Tokgozoglu, L., Dogan, V., Ceyhan, C., Tuncez, A., Kutlu, M., et al. (2018) What Have We Learned from Turkish Familial Hypercholesterolemia Registries (A-HIT1 and A-HIT2)? Atherosclerosis, 277, 341-346.
https://doi.org/10.1016/j.atherosclerosis.2018.08.012
|
[12]
|
Trinder, M., Vikulova, D., Pimstone, S., Mancini, G.B.J. and Brunham, L.R. (2022) Polygenic Architecture and Cardiovascular Risk of Familial Combined Hyperlipidemia. Ath-erosclerosis, 340, 35-43.
https://doi.org/10.1016/j.atherosclerosis.2021.11.032
|
[13]
|
Nawawi, H.M., Chua, Y.A. and Watts, G.F. (2020) The Brave New World of Genetic Testing in the Management of the Dyslipidaemias. Current Opinion in Cardiology, 35, 226-233. https://doi.org/10.1097/HCO.0000000000000721
|
[14]
|
Taghizadeh, E., Farahani, N., Mardani, R., et al. (2022) Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update. Biochemical Genetics, 60, 453-481. https://doi.org/10.1007/s10528-021-10130-2
|
[15]
|
Gill, P.K. and Hegele, R.A. (2022) Familial Combined Hyper-lipidemia Is a Polygenic Trait. Current Opinion in Lipidology, 33, 126-132. https://doi.org/10.1097/MOL.0000000000000796
|
[16]
|
Taghizadeh, E., Esfehani, R.J., Sahebkar, A., Parizadeh, S.M., Rostami, D., Mirinezhad, M., et al. (2019) Familial Combined Hyperlipidemia: An Overview of the Underlying Molecular Mechanisms and Therapeutic Strategies. IUBMB Life, 71, 1221-1229. https://doi.org/10.1002/iub.2073
|
[17]
|
Hopkins, P.N., Wu, L.L., Hunt, S.C. and Brinton, E.A. (2005) Plasma Tri-glycerides and Type III Hyperlipidemia Are Independently Associated with Premature Familial Coronary Artery Disease. Journal of the American College of Cardiology, 45, 1003-1012. https://doi.org/10.1016/j.jacc.2004.11.062
|
[18]
|
Riccardi, G., Vaccaro, O., Costabile, G. and Rivellese, A.A. (2016) How Well Can We Control Dyslipidemias through Lifestyle Modifications? Current Cardiology Reports, 18, Article No. 66. https://doi.org/10.1007/s11886-016-0744-7
|
[19]
|
Falko, J.M. (2018) Familial Chylomicronemia Syndrome: A Clinical Guide for Endocrinologists. Endocrine Practice, 24, 756-763. https://doi.org/10.4158/EP-2018-0157
|
[20]
|
Chou, R., Dana, T., Blazina, I., Daeges, M. and Jeanne, T.L. (2016) Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preven-tive Services Task Force. JAMA, 316, 2008-2024.
https://doi.org/10.1001/jama.2015.15629
|
[21]
|
Mills, E.J., O’Regan, C., Eyawo, O., Wu, P., Mills, F., Berwanger, O. and Briel, M. (2011) Intensive Statin Therapy Compared with Moderate Dosing for Prevention of Cardiovascular Events: A Meta-Analysis of > 40 000 Patients. European Heart Journal, 32, 1409-1415. https://doi.org/10.1093/eurheartj/ehr035
|
[22]
|
Cannon, C.P., Steinberg, B.A., Murphy, S.A., Mega, J.L. and Braunwald, E. (2006) Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive versus Moderate Statin Therapy. Journal of the American College of Cardiology, 48, 438-445. https://doi.org/10.1016/j.jacc.2006.04.070
|
[23]
|
Rodriguez, F., Maron, D.J., Knowles, J.W., Virani, S.S., Lin, S. and Heidenreich, P.A. (2017) Association between Intensity of Statin Therapy and Mortality in Patients with Atheroscle-rotic Cardiovascular Disease. JAMA Cardiology, 2, 47-54. https://doi.org/10.1001/jamacardio.2016.4052
|
[24]
|
Silva, M., Matthews, M.L., Jarvis, C., Nolan, N.M., Belliveau, P., Malloy, M. and Gandhi, P. (2007) Meta-Analysis of Drug-Induced Adverse Events Associated with Intensive-Dose Statin Therapy. Clinical Therapeutics, 29, 253-260.
https://doi.org/10.1016/j.clinthera.2007.02.008
|
[25]
|
Kim, B.K., Hong, S.J., Lee, Y.J., Hong, S.J., Yun, K.H., Hong, B.K., et al. (2022) Long-Term Efficacy and Safety of Moderate-Intensity Statin with Ezetimibe Combination Therapy versus High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease (RACING): A Ran-domised, Open-Label, Non-Inferiority Trial. The Lancet, 400, 380-390. https://doi.org/10.1016/S0140-6736(22)00916-3
|
[26]
|
Zhang, X., Xing, L., Jia, X., Pang, X., Xiang, Q., Zhao, X., et al. (2020) Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. Cardiovascular Therapeutics, 2020, Article ID: 3987065. https://doi.org/10.1155/2020/3987065
|
[27]
|
Awad, K. and Banach, M. (2018) The Optimal Time of Day for Statin Administration: A Review of Current Evidence. Current Opinion in Lipidology, 29, 340-345. https://doi.org/10.1097/MOL.0000000000000524
|
[28]
|
Awad, K., Serban, M.C., Penson, P., Mikhailidis, D.P., Toth, P.P., Jones, S.R., Rizzo, M., et al. (2017) Effects of Morning vs Evening Statin Administration on Lipid Profile: A Systematic Review and Meta-Analysis. Journal of Clinical Lipidology, 11, 972-985.E9. https://doi.org/10.1016/j.jacl.2017.06.001
|
[29]
|
高海洋, 汪芳. 他汀类药物导致肝损伤的诊断和监测[J]. 心血管病学进展, 2017, 38(3): 271-276.
https://doi.org/10.16806/j.cnki.issn.1004-3934.2017.03.008
|
[30]
|
Björnsson, E., Jacobsen, E.I. and Kalaitzakis, E. (2012) Hepatotoxicity Associated with Statins: Reports of Idiosyncratic Liver Injury Post-Marketing. Journal of Hepa-tology, 56, 374-380. https://doi.org/10.1016/j.jhep.2011.07.023
|
[31]
|
Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., Ray, K.K., et al. (2015) Statin-Associated Muscle Symptoms: Impact on Statin Thera-py-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 36, 1012-1022. https://doi.org/10.1093/eurheartj/ehv043
|
[32]
|
陈宇, 李银洛, 唐才林, 等. 瑞舒伐他汀引起新发糖尿病的研究进展[J]. 中国糖尿病杂志, 2022, 30(9): 712-714.
|
[33]
|
Mach, F., Ray, K.K., Wiklund, O., Corsini, A., Catapano, A.L., Bruckert, E., et al. (2018) Adverse Effects of Statin Therapy: Perception vs. the Evi-dence—Focus on Glucose Homeostasis, Cognitive, Renal and Hepatic Function, Haemorrhagic Stroke and Cataract. Eu-ropean Heart Journal, 39, 2526-2539. https://doi.org/10.1093/eurheartj/ehy182
|
[34]
|
Capps, N. (2006) Total and Low-Density Lipoprotein Cholesterol Responses to Ezetimibe in Clinical Practice. International Journal of Clinical Prac-tice, 60, 867-869. https://doi.org/10.1111/j.1368-5031.2006.00958.x
|
[35]
|
王依繁, 张翼, 林阳. 他汀类药物联合依折麦布用于冠心病患者治疗的有效性和安全性评价[J]. 中国医院药学杂志, 2022, 42(5): 538-543. https://doi.org/10.13286/j.1001-5213.2022.05.14
|
[36]
|
中等强度他汀+依折麦布, 优于单用高强度他汀[J]. 中国循证心血管医学杂志, 2023, 15(5): 634.
|
[37]
|
Phan, B.A., Dayspring, T.D. and Toth, P.P. (2012) Ezetimibe Therapy: Mechanism of Action and Clinical Update. Vascular Health and Risk Management, 8, 415-427. https://doi.org/10.2147/VHRM.S33664
|
[38]
|
Chen, W., Ruan, Z., Chen, J., Yang, D., Shao, R., Lou, H. and Jiang, B. (2022) Population Pharmacokinetics and Enterohepatic Recirculation of Hyzetimibe and Its Main Metabolite in Chi-nese Healthy Subjects. British Journal of Clinical Pharmacology, 88, 3153-3161. https://doi.org/10.1111/bcp.15187
|
[39]
|
Ballantyne, C.M., Banka, P., Mendez, G., Garcia, R., Rosenstock, J., Rodgers, A., Mendizabal, G., Mitchel, Y. and Catapano, A.L. (2023) Phase 2b Randomized Trial of the Oral PCSK9 In-hibitor MK-0616. Journal of the American College of Cardiology, 81, 1553-1564. https://doi.org/10.1016/j.jacc.2023.02.018
|
[40]
|
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B.E., Camaj, A., Kalkman, D.N., et al. (2019) Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Me-ta-Analysis of Randomized Controlled Trials. European Heart Journal, 43, e17-e25. https://doi.org/10.1093/eurheartj/ehz430
|
[41]
|
Pokhrel, B., Yuet, W.C. and Levine, S.N. (2023) PCSK9 Inhibitors. StatPearls Publishing, Treasure Island.
|
[42]
|
Pirillo, A., Catapano, A.L. and Norata, G.D. (2021) Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. Current Atheroscle-rosis Reports, 23, Article No. 79.
https://doi.org/10.1007/s11883-021-00972-x
|
[43]
|
Ge, X., Zhu, T., Zeng, H., Yu, X., Li, J., Xie, S., et al. (2021) A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia. BioMed Research International, 2021, Article ID: 8032978. https://doi.org/10.1155/2021/8032978
|
[44]
|
Gallego-Colon, E., Daum, A. and Yosefy, C. (2020) Statins and PCSK9 Inhibitors: A New Lipid-Lowering Therapy. European Journal of Pharmacology, 878, Article ID: 173114. https://doi.org/10.1016/j.ejphar.2020.173114
|
[45]
|
Ray, K.K., Wright, R.S., Kallend, D., Koenig, W., Leiter, L.A., Raal, F.J., et al. (2020) Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England Journal of Medicine, 382, 1507-1519.
https://doi.org/10.1056/NEJMoa1912387
|
[46]
|
Warden, B.A. and Duell, P.B. (2021) Inclisiran: A Novel Agent for Lowering Apolipoprotein B-Containing Lipoproteins. Journal of Cardiovascular Pharmacology, 78, E157-E174. https://doi.org/10.1097/FJC.0000000000001053
|
[47]
|
Yamashita, S., Masuda, D. and Matsuzawa, Y. (2020) Pem-afibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Current Atherosclerosis Reports, 22, Article No. 5. https://doi.org/10.1007/s11883-020-0823-5
|
[48]
|
Julius, U. and Fischer, S. (2013) Nicotinic Acid as a Li-pid-Modifying Drug—A Review. Atherosclerosis Supplements, 14, 7-13. https://doi.org/10.1016/j.atherosclerosissup.2012.10.036
|
[49]
|
HPS2-THRIVE Collaborative Group, Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., Tomson, J., et al. (2014) Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. The New England Journal of Medicine, 371, 203-212. https://doi.org/10.1056/NEJMoa1300955
|
[50]
|
AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Teo, K. and Weintraub, W. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. The New England Journal of Medicine, 365, 2255-2267.
https://doi.org/10.1056/NEJMoa1107579
|
[51]
|
HPS2-THRIVE Collaborative Group; Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., Tomson, J., Wallendszus, K., Craig, M., Jiang, L., Collins, R. and Armitage, J. (2014) Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. The New England Journal of Medi-cine, 371, 203-212.
|
[52]
|
Laufs, U., Banach, M., Mancini, G.B.J., Gaudet, D., Bloedon, L.T., Sterling, L.R., Kelly, S. and Stroes, E.S.G. (2019) Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin In-tolerance. Journal of the American Heart Association, 8, E011662. https://doi.org/10.1161/JAHA.118.011662
|
[53]
|
Nissen, S.E., Lincoff, A.M., Brennan, D., Ray, K.K., Mason, D., Kastelein, J.J.P., et al. (2023) Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. The New Eng-land Journal of Medicine, 388, 1353-1364.
https://doi.org/10.1056/NEJMoa2215024
|
[54]
|
Ballantyne, C.M., Laufs, U., Ray, K.K., Leiter, L.A., Bays, H.E., Goldberg, A.C., et al. (2020) Bempedoic Acid plus Ezetimibe Fixed-Dose Combination in Patients with Hypercholester-olemia and High CVD Risk Treated with Maximally Tolerated Statin Therapy. European Journal of Preventive Cardiol-ogy, 27, 593-603.
https://doi.org/10.1177/2047487319864671.
|
[55]
|
Markham, A. (2021) Evinacumab: First Approval. Drugs, 81, 1101-1105. https://doi.org/10.1007/s40265-021-01516-y
|
[56]
|
Feingold, K.R. (2021) Triglyceride Lowering Drugs. In: Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., De Herder, W.W., Dhatariya, K., et al., Eds., Endotext, MDText.Com, Inc., South Dartmouth, 2000.
|
[57]
|
Watanabe, Y. and Tatsuno, I. (2020) Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. Journal of Athero-sclerosis and Thrombosis, 27, 183-198.
https://doi.org/10.5551/jat.50658
|
[58]
|
Kirkpatrick, C.F., Sikand, G., Petersen, K.S., Anderson, C.A.M., Aspry, K.E., Bolick, J.P., Kris-Etherton, P.M. and Maki, K.C. (2023) Nutrition Interventions for Adults with Dyslipidemia: A Clinical Perspective from the National Lipid Association. Journal of Clinical Lipidology, 17, 428-451. https://doi.org/10.1016/j.jacl.2023.05.099
|
[59]
|
Nie, Y. and Luo, F. (2021) Dietary Fiber: An Opportunity for a Global Control of Hyperlipidemia. Oxidative Medicine and Cellular Longevity, 2021, Article ID: 5542342. https://doi.org/10.1155/2021/5542342
|
[60]
|
Makhmudova, U., Schulze, P.C., Lütjohann, D. and Weingärtner, O. (2021) Phytosterols and Cardiovascular Disease. Current Atherosclerosis Reports, 23, Article No. 68. https://doi.org/10.1007/s11883-021-00964-x
|
[61]
|
Zhao, S., Zhong, J., Sun, C. and Zhang, J. (2021) Effects of Aerobic Exercise on TC, HDL-C, LDL-C and TG in Patients with Hyperlipidemia: A Protocol of Systematic Review and Meta-Analysis. Medicine (Baltimore), 100, E25103.
https://doi.org/10.1097/MD.0000000000025103
|
[62]
|
De Matos, D.G., De Almeida-Neto, P.F., Moreira, O.C., De Souza, R.F., Tinoco Cabral, B.G.A., Chilibeck, P. and Aidar, F.J. (2021) Two Weekly Sessions of High-Intensity Inter-val Training Improve Metabolic Syndrome and Hypertriglyceridemic Waist Phenotype in Older Adults: A Randomized Controlled Trial. Metabolic Syndrome and Related Disorders, 19, 332-339. https://doi.org/10.1089/met.2020.0136
|